KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Convertible Debt (2022 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Convertible Debt for 5 consecutive years, with $1.0 billion as the latest value for Q1 2026.

  • For Q1 2026, Convertible Debt fell 1.58% year-over-year to $1.0 billion; the TTM value through Mar 2026 reached $1.0 billion, down 1.58%, while the annual FY2025 figure was $1.0 billion, 1.64% down from the prior year.
  • Convertible Debt hit $1.0 billion in Q1 2026 for Alnylam Pharmaceuticals, roughly flat from $1.0 billion in the prior quarter.
  • Across five years, Convertible Debt topped out at $1.0 billion in Q3 2025 and bottomed at $1.0 billion in Q4 2025.
  • Average Convertible Debt over 5 years is $1.0 billion, with a median of $1.0 billion recorded in 2023.
  • On a YoY basis, Convertible Debt climbed as much as 1.62% in 2025 and fell as far as 1.64% in 2025.
  • Alnylam Pharmaceuticals' Convertible Debt stood at $1.0 billion in 2022, then grew by 0.38% to $1.0 billion in 2023, then increased by 0.38% to $1.0 billion in 2024, then fell by 1.64% to $1.0 billion in 2025, then increased by 0.16% to $1.0 billion in 2026.
  • According to Business Quant data, Convertible Debt over the past three periods came in at $1.0 billion, $1.0 billion, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.